Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation

(2009) A. Larange et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Antitumor Effects of an Imidazoquinoline in Renal Cell Carcinoma

(2009) Michael J. Schwartz et al.   UROLOGY

Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology

(2008) S. Baenziger et al.   BLOOD

A phase II dose-ranging study of topical resiquimod to treat actinic keratosis

(2008) R.-M. Szeimies et al.   BRITISH JOURNAL OF DERMATOLOGY

NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model

(2008) Calin D. Dumitru et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Christian Manegold et al.   JOURNAL OF CLINICAL ONCOLOGY

The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy

(2008) E. L. J. M. Smits et al.   ONCOLOGIST